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Introduction
Although breast cancer (BC) mortality rates are decreasing, 
most likely because of efficient screening strategies, BC still 
is the leading cause of cancer-related deaths in women world-
wide.1 Current BC therapy depends on the type and stage of 
the BC and traditionally consists of a multivariate approach 
including surgery, hormone therapy, systemic chemotherapy, 
radiotherapy, and molecular targeted therapy.2 However, 
one prerequisite for a hormone therapy is the expression of 
estrogen or progesterone receptors (ER and PgR, respec-
tively) in the cancer cells. These ER and PgR positive cancers 
account for about 75–80% of the diagnosed BCs, whereas 
about 10–15% are diagnosed as triple negative (TN) BC. 
These subtypes of BC lack not only the expression of ER and 
PgR, but also overexpression of human epidermal growth 
factor receptor 2 (HER2). Currently, chemo- and molecular-
targeted therapies are the only systemic approaches for these 
malignancies.3,4
One promising molecular target is the phosphatidylinos-
itol 3-kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) pathway, because it is frequently mutated in human 
cancers and its activation alters a number of cellular processes 
that are stimulating proliferation, cell growth, and survival.5 
Furthermore, activation of this pathway has been shown to 
decrease sensitivity to chemotherapeutics as well as to irradia-
tion (IR),6,7 resulting in diminished treatment success.
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However, radiosensitivity is determined not only by the 
cells’ intrinsic radioresistance, which can be modulated with 
radiosensitizing agents, but also by the surrounding microen-
vironment, especially by the oxygen saturation. According to 
Vaupel et al., a median oxygen partial pressure of 65 mmHg 
(8.67 kPa) and 30 mmHg (4.00 kPa) was observed in normal 
breast and BC tissue,8 corresponding to an oxygen content 
of 8.5 and 4.0%, respectively. However, oxygen concen-
tration within these hypoxic areas differs with the biggest 
subgroup showing a partial pressure of about 5–7.5 mmHg 
(0.66–1.00 kPa),8 which confers to an oxygen content of 
about 1%. Especially, these hypoxic regions in solid malig-
nancies, as occurring in about 40% of all BC,9 reveal various 
changes in pro-survival gene expression, suppressed apopto-
sis, as well as increased invasiveness, metastasis, and genomic 
instability.10,11
In solid tumors, three different cell subpopulations exist 
because of changes in the microregional blood flow: normoxic 
cells, cells that are subjected to intermittent hypoxia and 
hypoxic cells.12–14 Because these subpopulations differ in their 
biology and have different resistances to chemo- and radio-
therapy, all three should be taken into account, when investi-
gating the efficiency of novel drugs.15–17
The hypoxia-induced changes, which are linked to 
increased radioresistance, are intertwined with the PI3K/Akt/
mTOR pathway, outlining this signaling network as a prom-
ising target for a radiosensitizing approach in normoxic and 
hypoxic conditions.18–20 In fact, the novel orally available dual 
PI3K/mTOR inhibitor NVP-BEZ235, which is currently 
used in clinical trials as a chemotherapeutic drug,21 already 
showed promising cytostatic results in BC treatment,22,23 and 
revealed a radiosensitizing potential in hypopharyngeal and 
prostate cancer cells under normoxic and harsh hypoxic con-
ditions.24,25 However, no study is published yet that validated 
these promising results in the physiological relevant condi-
tions of mild intermittent hypoxia in BC cell lines.8
To prove whether the dual PI3K/mTOR inhibitor radi-
osensitizes BC cells, we treated TN MDA-MB-231 and 
ER-positive MCF-7 cells with NVP-BEZ235, concomi-
tantly simulating the clinically relevant oxygenation states of 
normoxic, reoxygenated after IR, and hypoxic tumor cells. 
After determining the cytotoxicity of NVP-BEZ235, we 
cultured cells in normoxic, reoxygenated, or hypoxic condi-
tions and assessed the colony-forming ability, the cell cycle 
distributions, and the induction and decay of DNA double-
strand breaks (DSBs) after IR. Furthermore, we investigated 
the incidence of apoptosis markers (hypodiploid cells and poly 
(ADP-ribose) polymerase (PARP) cleavage), and the expres-
sion of the hypoxia-inducible factor 1-alpha (HIF-1α), several 
PI3K/Akt/mTOR pathways (PI3K p110, PI3k p85, p-Akt, 
Akt, p-mTOR, mTOR, p-S6, S6, and p-4E-BP1), and 
autophagy-related proteins (LC3-I and LC3-II).
Materials and Methods
cell culture and drug treatment. The human BC cell 
lines MCF-7 and MB-231 were obtained from the “Cell 
Lines Services” company (Heidelberg, Germany) and rou-
tinely cultured under standard conditions (37 °C, 5% CO2) 
in complete growth medium (CGM), which was Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal 
bovine serum and 5% glutamine. To compare normoxic, 
reoxygenated, and hypoxic cells, 5 × 105 cells were allowed to 
attach in standard 75 cm2 tissue culture flasks (Greiner Bio-
One, Frickenhausen, Germany) for six hours before cells for 
reoxygenation and hypoxia experiments were transferred into 
a hypoxic glove box (Coy Laboratory Products, Grass Lake, 
USA) and cultured at 1% O2, which is a partial pressure of 
approximately 8 mmHg, thus reflecting a mild hypoxia in 
tumor tissue, overnight. For reoxygenation, experiments cells 
were incubated under standard conditions after IR, whereas 
cells of hypoxia experiments were further cultured at 1% O2 
after IR until harvest or seeding in the case of colony-forming 
assays (compare Figure 1).
For all experiments, except cell viability assay, cells 
were treated one hour before IR with 100 nM of the dual 
PI3K/mTOR inhibitor NVP-BEZ235,26 which was pro-
vided by Novartis Institutes for BioMedical Research (Basel, 
Switzerland). The drug was freshly diluted from frozen ali-
quots stored at −20 °C. Cells treated in parallel with respective 
amounts of dimethyl sulfoxide (DMSO) served as controls.
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figure 1. A flowchart of cell culture in this study. Normoxic cells were kept under 21% O2 throughout the experiment. For the reoxygenation setup, cells 
were kept under hypoxic conditions (1% O2) until IR and were cultivated at 21% O2 afterward. For the hypoxia experiments, cells were cultivated in hypoxic 
conditions before and after ir. in all oxygenation setups, cells were treated with 100 nM nVP-BeZ235 one hour before ir. For colony-forming assays, 
cells were cultivated for 24 hours after ir in indicated oxygen concentrations before plating of the cells. For Western blot, cell cycle, γh2aX, and sub 
G1 measurements cells were fixed at 30 minutes, 24 hours, and 48 hours after IR.
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X-ray Ir. IR was performed at room temperature using a 
6-MV Siemens linear accelerator (Siemens, Concord, USA) at 
a dose rate of 2 Gy/minute. After IR, cells were kept in CGM 
according to the treatment schedule, for the indicated time 
until harvest.
cell viability assay. To examine the cytotoxic effects 
of NVP-BEZ235, we used the CellTiter 96 AQueous One 
Solution (Promega, Madison, USA) according to the man-
ufacturer’s instructions. Serial dilutions of NVP-BEZ235 
(6.25–800 nM) in CGM were added to normoxic (21% O2) 
and hypoxic (1% O2) cell cultures in quadruplicates, and the 
cytotoxicity of the drug was determined 24 hours later. Further 
analysis of the data was basically as described previously.27
colony-forming assay. Colony-forming assay was per-
formed, and data were analyzed as described elsewhere.27,28 
Briefly, subconfluent monolayers of cells were treated with 
100 nM NVP-BEZ235 or respective amounts of DMSO one 
hour before IR with graded single doses (0–8 Gy) at room 
temperature. Twenty-four hours after IR, cells were seeded 
in Petri dishes and cultivated in CGM under standard condi-
tions for two weeks. Colonies were stained with 0.6% crystal 
violet, and colonies containing more than 50 cells were scored 
as survivors. Experiments were done in quadruplicate, and 
each experiment was repeated at least three times.
western blot. After preparation of nuclear extracts or 
whole cell lysates according to standard protocols, samples 
equivalent to 10–40 µg of protein were separated according to 
their protein size using 4–12% sodium-dodecyl-sulfate-poly-
acrylamide pre-cast gels (Invitrogen, Karlsruhe, Germany) 
and transferred to nitrocellulose membranes. Membranes were 
incubated with protein-specific primary and species-specific 
peroxidase-labeled secondary antibody for protein detection. 
The protein expression levels were quantified using ImageJ 
(NIH, Bethesda, USA), and protein expression was normal-
ized to the levels of β-tubulin (nuclear extracts) or β-actin 
(whole cell lysates).
Antibodies. The antibodies used in the experiments of 
this article are specified in the electronic supplementary mate-
rial (ESM).
detection of histone γH2AX, cell cycle distribu-
tion, and measurement of hypodiploid cell fraction by flow 
cytometry. To quantify IR and/or drug-induced DNA DSBs, 
we assessed the phosphorylation of the histone H2AX.29 To 
this end, drug-treated and DMSO-treated cells were fixed for 
further analysis at 30 minutes, 24 hours, and 48 hours after 
IR. Staining and analysis of the fixed samples were performed 
essentially as described elsewhere.30 Cells were counterstained 
with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) 
(Sigma-Aldrich, Munich, Germany) in the presence of RNase 
A (Sigma-Aldrich, Munich, Germany), to assess cell cycle 
distribution and to quantify cells with a hypodiploid DNA 
content. At least 20,000 cells were assessed simultaneously 
for histone γH2AX and DNA content using a flow cytometer 
FACSCanto II (Becton Dickinson, San Jose, USA). Analysis 
of the acquired data, calculation of the geometric mean flu-
orescence intensity (MFI) of FITC, and deconvolution of 
DNA histogram were performed using the Flowing Software 
program obtained from P. Terho (Turku Centre for Biotech-
nology, Turku, Finland) and the ModFit LT program (Verity 
Software House, Topsham, USA).
statistics. Data are presented as means ± standard devia-
tion of at least three independent experiments. Unpaired t-tests 
were performed, and P-value less than 0.05 was considered to 
be statistically significant. For multiple comparisons, Holm–
Bonferroni method of alpha error correction was applied. Sta-
tistics and fitting of experimental data were performed with 
RStudio 0.96.331 (Free Software Foundation, Boston, USA) 
and Origin 8.5 (Microcal, Northampton, USA).
results
NVP-beZ235 decreased cell proliferation and sen-
sitized cells to Ir independent of oxygen supply. To assess 
the effects of NVP-BEZ235 on proliferation of MDA-
MB-231 and MCF-7 cells, we treated both cell lines with 
serial dilutions of the dual inhibitor within a concentration 
range of 6.25–800 nM and quantified cell viability by an 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based assay. For-
mazan production, detected by absorbance at 492 nm, in 
drug-treated samples was normalized against controls treated 
with DMSO and plotted versus drug concentration. As evi-
dent from Figure 2, incubation of normoxic cells for 24 hours 
with increasing NVP-BEZ235 concentrations decreased cell 
proliferation to about 75 and 65% of the initial level in MDA-
MB-231 and MCF-7 cells, respectively. Interestingly, drug 
exposure in hypoxic culture conditions resulted in superior 
growth inhibition, compared to normoxic samples, to about 
55% of the control levels in both cell lines. For subsequent 
experiments, we used a drug concentration of 100 nM, which 
inhibited cell proliferation to about 80% of the maximal effect 
(IC80) in both cell lines and which is in line with previously 
published experiments.26,27,31
To ensure that the radiosensitivity of the examined cell 
lines depends on oxygen saturation, we performed colony for-
mation assays with cells cultured in different oxygen condi-
tions. As shown in Figure 3, hypoxic cells were more resistant 
to radiation, showing increased surviving fractions depending 
on the oxygen partial pressure. For the following hypoxia and 
reoxygenation experiments, we used an oxygen concentra-
tion of 1%, which showed statistical significant differences in 
terms of radiosensitivity compared to normoxic controls and 
which is in line with the predominant physiological condition 
of a mild hypoxia in BC.8
To address the question, whether treatment with 100 nM 
NVP-BEZ235 sensitizes the BC cell lines to IR and if this 
radiosensitization is affected by the oxygenation status, we 
performed colony-forming assays (Fig. 4A). Hypoxic culture 
conditions were validated by elevated HIF-1α expression in 
Kuger et al
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hypoxic and reoxygenated samples (Fig. 4B). As expected, 
HIF-1α expression was reduced in reoxygenated cells over 
time. Interestingly, prolonged incubation with NVP-BEZ235 
also somewhat decreased the HIF-1α expression in hypoxic 
samples, as shown in Figure 4B and ESM Figure 1B.
Figure 4A shows representative normalized cell survival 
responses of drug-treated MCF-7 cells and DMSO-treated 
controls after IR with doses from 0 to 8 Gy under differ-
ent oxygen conditions. The MDA-MB-231 cell line showed 
qualitative similar results (ESM Figure 1A). At least three 
independent experiments were performed, and the radiation 
dose yielding 10% survival (D10) and the surviving fraction at 
2 Gy (SF2), as well as the plating efficiencies and the oxygen 
enhancement ratios for the D10 (OER D10) and the SF2 
(OER SF2) are summarized in ESM Figure 2.
As apparent in ESM Figure 2, the plating efficiency was not 
significantly influenced by hypoxia or NVP-BEZ235 in both 
cell lines. However, in both cell lines reoxygenated and hypoxic 
untreated cells were statistically significant more resistant to 
IR than normoxic cells. In both cell lines, the calculated OER 
D10 and OER SF2 were about 1.3 and 1.4 for hypoxic and 
reoxygenated cells, respectively (ESM Figure 2C–F). No sig-
nificant changes between reoxygenated and hypoxic DMSO-
treated cells were detected in both cell lines. Most strikingly, 
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treatment with NVP-BEZ235 statistically significant 
radiosensitized both cell lines independent of oxygen supply 
(Fig. 4A, ESM Figure 1A, and ESM Figure 2C–F). More-
over, treatment with the dual PI3K/mTOR inhibitor totally 
circumvented the negative effects of hypoxia on the radio-
sensibility, as shown by almost equal D10 and SF2 values for 
NVP-BEZ235-treated samples independent of their oxygen-
ation status (ESM Figure 2C–F).
NVP-beZ235 suppresses activity of the PI3K/Akt/
mtor pathway. To investigate the molecular reasons for 
the NVP-BEZ235-induced increased radiosensitivity of 
tumor cells, which was independent of cellular oxygenation 
status, we assessed the expression of several relevant proteins 
of the PI3K/Akt/mTOR signaling cascade after combined 
drug-IR treatment in normoxic, reoxygenated, and hypoxic 
cells.
As shown in Figure 5, incubation with NVP-
BEZ235 inactivated the PI3K/AKT/mTOR signaling cascade 
independent of cellular oxygenation status, as indicated by 
decreased phosphorylation of Akt, mTOR, S6, and 4E-BP1. 
This effect was observed up to 48 hours after IR in the MCF-7 
cell line (ESM Figure 3A and B). None or only minor changes 
were observed in protein expression of PI3K subunits p110 
and p85, AKT, mTOR, and S6.
In general, the MDA-MB-231 cells showed qualitatively 
similar data for the expression of the tested PI3K/Akt/mTOR 
pathway proteins, with the exception of p-Akt, which was not 
detectable in MDA-MB-231 cells. Furthermore, phosphory-
lation of mTOR was diminished 30 minutes after IR in NVP-
BEZ235-treated cells, but mTOR phosphorylation was not 
suppressed after prolonged incubation with NVP-BEZ235 
(ESM Figure 3C–E). However, as proven by diminished S6 
and 4E-BP1 phosphorylation, treatment with NVP-BEZ235 
led to inactivation of mTOR signaling in both BC cell lines in 
all three oxygenation states tested in this study.
NVP-beZ235 induces programmed cell death and 
autophagy. To further elucidate the molecular reasons for 
the NVP-BEZ235-mediated radiosensitization, we assessed 
the induction of programmed cell death in cells treated with 
the dual PI3K/mTOR inhibitor and IR under different 
oxygen conditions. Figure 6A summarizes three independent 
experiments and shows the mean percentage of cells with 
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β-tubulin intensity, and changes in protein expression are denoted by numbers.
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hypodiploid DNA content and cellular debris, a marker for 
late stage apoptosis, in MCF-7 cells 48 hours after IR. Cells 
were cultivated under normoxic, reoxygenated, and hypoxic 
conditions, and treated with NVP-BEZ235 (gray columns) 
one hour before IR with 8 Gy (striped columns). Oxygenation 
status did not affect late stage apoptosis in untreated and 
non-irradiated MCF-7 cells (white non-striped columns). 
However, exposing MCF-7 cells to IR caused a statistical sig-
nificant increase in hypodiploid cells, indicating cell death, 
independent of oxygenation status.
Furthermore, treatment with the dual PI3K/mTOR 
inhibitor induced apoptosis as well, as shown by statistical sig-
nificant increases in hypodiploid fractions at all oxygen con-
ditions tested. Combining IR and NVP-BEZ235 treatment 
(gray striped column) enhanced cell death in the MCF-7 cell 
line independent of oxygenation status, as seen by a statisti-
cal significant increase in hypodiploid cells and cellular debris 
compared to IR or drug-treated cells alone.
As shown in ESM Figure 4A, the response of MDA-
MB-231 cells was somewhat different. Treatment with 
NVP-BEZ235 did not cause any significant changes in the 
percentage of hypodiploid cells and debris in all oxygen 
conditions. However, exposing MDA-MB-231 cells to IR 
increased apoptosis, but in contrast to MCF-7 cells, this 
apoptosis was not statistically significantly enhanced by 
dual PI3K/mTOR inhibition, although tendencies were 
noticeable.
Furthermore, we probed for the expression and cleav-
age of the DNA repair enzyme PARP and for expression 
of the autophagy markers LC3-I and LC3-II. Figure 6B 
and ESM Figure 4B show samples of MCF-7 and MDA-
MB-231 cells, respectively, which were collected 48 hours 
after IR and cultivated in normoxic, reoxygenated, or 
hypoxic conditions. Treatment of the MCF-7 cell line with 
NVP-BEZ234 caused a decrease in PARP levels in all oxy-
gen conditions, most likely by PARP degradation, indicated 
by increased cleaved PARP levels. In line with the previous 
shown data for late stage apoptosis (Fig. 6A), combined dual 
PI3K/mTOR inhibition and IR caused the highest levels of 
cleaved PARP.
To assess the impact of NVP-BEZ235 and IR on 
the induction of autophagy, we probed for the autophagy 
marker protein LC3, which is converted from the cytosolic 
soluble LC3-I to the membrane-bound LC3-II form during 
autophagy. As shown in Figure 6B, treatment of MCF-7 cells 
with NVP-BEZ235 caused a strong decrease in LC3-I 
Normoxia Reoxygenation Hypoxia
8 Gy 8 Gy 8 Gy0 Gy
Control
0.39 0.68 0.35 0.54 0.61 0.65
MCF-7
PI3K p110
PI3K p85
AKT
p-AKT
mTOR
p-mTOR
S6
p-S6
p-4E-BP1
Control Control Control Control ControlBEZ235
n.d. n.d. n.d. n.d. n.d. n.d.
0.81 0.72 0.60 0.56 0.77 0.460.61 0.50 0.45 0.27 0.30 0.16
0.94 0.89 0.80 0.86 1.16 1.110.30 0.29 0.16 0.26 0.22 0.17
1.40 1.42 1.17 1.21 1.62 1.670.18 0.14 <0.1 0.14 0.12 <0.1
BEZ235 BEZ235 BEZ235 BEZ235 BEZ235
0 Gy 0 Gy
figure 5. representative Western blot analysis of expression levels of several marker proteins of the Pi3K pathway in MCF-7 cellular lysates, prepared 
30 minutes after ir. Cells were treated with nVP-BeZ235 or dMsO before ir at 8 Gy and cultivated under normoxic, reoxygenated, or hypoxic 
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48 hours after IR in all drug-treated samples, but no enrich-
ment of LC3-II was observed.
ESM Figure 4B shows that the cellular response of 
MDA-MB-231 cells in terms of PARP expression and cleav-
age is also in line with the previous shown data for late stage 
apoptosis (ESM Figure 4A). Exposing MDA-MB-231 cells to 
IR caused a slight increase in PARP cleavage, but in contrast to 
the MCF-7 cell line, treatment with NVP-BEZ235 caused only 
minor changes in PARP cleavage independent of oxygenation 
status. However, NVP-BEZ235-mediated depletion of LC3-I 
protein was observable 48 hours after IR in MDA-MB-231 cells 
in all tested oxygenation conditions as well (ESM Figure 4B).
effect of oxygenation status, NVP-beZ235, and Ir on 
cell cycle and dNA damage. To further explore the molecular 
basis for the radiosensitizing effect of the dual PI3K/mTOR 
inhibitor, we assessed if cell cycle alterations and DNA DSBs 
were observable after NVP-BEZ235 treatment and/or IR. The 
summarized data for the cell cycle phase distributions and the 
normalized DNA DSBs of at least three independent experiments 
are shown in ESM Figure 5 and ESM Figure 6, respectively.
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flow cytometry. The columns display means (± standard deviation) of hypodiploid nuclei and cellular debris of at least three independent experiments. 
Statistical comparisons between controls were omitted for reasons of clarity. Statistically significant differences are indicated as follows: #P , 0.05, 
##P , 0.01, and ###P , 0.001. representative Western blot analysis of expression levels of apoptosis and autophagy-relevant proteins in MCF-7 cellular 
lysates, prepared 48 hours after ir (B). Cells were cultivated under normoxic, reoxygenated, or hypoxic conditions and treated with nVP-BeZ235 or 
dMsO before ir at 8 Gy. Protein bands were normalized to the β-actin intensity, and changes in protein expression are denoted by numbers. the 
experiment was repeated at least three times. n.d. indicates not determinable.
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As expected, neither NVP-BEZ235 nor IR had effects 
on the cell cycle phase distribution 30 minutes after IR (ESM 
Figure 5). After 24 hours, the response to IR was different in 
the two cell lines. While MDA-MB-231 cells accumulated in 
the G2/M-phase, MCF-7 cells were arrested in the G1-phase. 
However, 48 hours after IR, the cell cycle phase distribu-
tion of irradiated control cells began to normalize, whereas 
in NVP-BEZ235-treated cells a significant higher amount 
of G2/M-phase cells was detected. This indicated a stable 
G2/M-phase arrest. Furthermore, we observed an arrest of 
non-irradiated cells in the G1-phase after prolonged incuba-
tion with the dual PI3K/mTOR inhibitor in both cell lines 
independent of oxygenation status.
As shown in ESM Figure 6, treatment of cells with 
NVP-BEZ235 caused diminished H2AX phosphorylation 
30 minutes after IR, representing less DNA damage than 
in irradiated control cells. However, with increasing repair 
time, DNA DSBs’ content was significantly higher in NVP-
BEZ235-treated and irradiated cells compared to irradiated 
controls, indicating protracted DNA repair. Noteworthy, 
and in line with the results of the apoptosis assays, prolonged 
incubation of MCF-7 cells with NVP-BEZ235 caused a 
γH2AX increase in non-irradiated cells. All the aforemen-
tioned effects on DNA damage induction and repair were 
observed independent of the oxygenation condition.
discussion
Targeting the anti-apoptotic PI3K/AKT/mTOR pathway to 
improve cancer control has been an intense and promising 
research field within the last decades. However, first-generation 
inhibitors of this pathway, such as wortmannin, LY294002, or 
rapamycin and its derivatives, demonstrated undesirable side 
effects and low specificity in some experiments.32–34 Therefore, 
second-generation inhibitors with improved specificity and 
pharmacological properties have been developed and are in 
clinical trials currently.26,35,36 One of these second-generation 
inhibitors is the novel orally available dual PI3K/mTOR inhib-
itor NVP-BEZ235. This imidazo[4,5-c]quinoline derivative 
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figure 7. A simplified diagram of putative signaling pathways accounting for the radiosensitization of MDA-MB-231 (a) and MCF-7 cells (B) treated with 
the dual Pi3K/mtOr inhibitor nVP-BeZ235 in normoxic and hypoxic conditions. incubation of tumor cells with nVP-BeZ235 for one hour before and up 
to 48 hours after ir decreases hiF-1α expression in hypoxic cells (Fig. 4 and esM Figures 1 and 2), circumventing the negative effect of hypoxia in terms 
of radiosensitivity (Fig. 3). Furthermore, nVP-BeZ235 treatment inactivates the Pi3K/aKt/mtOr signaling cascade, proven by dephosphorylation of aKt, 
mtOr, s6, and 4e-BP1 (Fig. 5 and esM Figure 3), which in the case of 4e-BP1 causes an activation of the translational repressor protein. inactivation 
of mtOr subsequently induces autophagy (Fig. 6B and esM Figure 4B) and diminishes proliferation. apart from these effects, dephosphorylation of 
aKt and mtOr by nVP-BeZ235 increases radiosensitivity. this increase in radiosensitivity, caused by reduction in hiF-1α expression, inactivation of 
the PI3K/AKT/mTOR signaling cascade, and may be also by other not yet identified NVP-BEZ235-induced mechanisms, causes an increase in residual 
dna damages (detected by γH2AX immunofluorescence) after IR (ESM Figure 6). These unrepaired, IR-induced DNA damages subsequently result in a 
prolonged G2/M-phase arrest (esM Figure 5), which further diminishes proliferation. apart from the effects already mentioned for the Mda-MB-231 cell 
line, prolonged incubation with nVP-BeZ235 induces dna damages (esM Figure 6) and enhances ir-induced apoptosis in MCF-7 cells (Fig. 6).
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demonstrated anti-proliferative and radiosensitizing activity 
in various in vitro and in vivo studies.24,27,31,37–44 Although, 
there is evidence that NVP-BEZ235 is able to sensitize fib-
rosarcoma as well as pharynx and prostate carcinoma cells to 
IR in normoxic and harsh hypoxic conditions,24,25 up-to-date 
no data are available about the radiosensitizing potential of 
NVP-BEZ235 in BC cell lines.
This study was designed to prove whether treatment with 
the dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes the 
TN BC cell line MDA-MB-231 and the ER-positive cell line 
MCF-7 to IR in three different clinically relevant oxygen con-
ditions: normoxic, reoxygenated after IR, and hypoxic.
The observed effects of NVP-BEZ235-mediated radio-
sensitization are summarized as a schematic pathway in 
Figure 7.
In our experiments, treatment with the dual inhibitor 
reduced carbonic anhydrase 9 (data not shown) and HIF-1α 
(Fig. 4) expression in hypoxic cells, which is in line with pre-
vious results.45 This is of utmost interest, because HIF-1α is a 
promising target for radiosensitization of tumors.13,46 Fokas 
et al. recently showed that dual PI3K/mTOR inhibition nor-
malized the aberrant vascular system in tumor xenografts.24 
However, apart from normalizing the vascular system, the 
exact molecular mechanism, in which the PI3K/AKT/mTOR 
pathway regulates HIF-1α expression, is not completely 
understood yet. As our in vitro data show that inhibition of 
HIF-1α is also an important feature of NVP-BEZ235-medi-
ated radiosensitization of hypoxic cells, this effect is worth to 
be evaluated in future experiments.
Another prime target for radiosensitizing approaches is 
the PI3K/AKT/mTOR pathway, which is activated in the 
majority of cancers.5,47 As shown, treatment with the dual 
inhibitor caused dephosphorylation of AKT, mTOR, S6, and 
4E-BP1, which in the case of 4E-BP1 causes activation of the 
translational repressor protein. Especially, AKT and mTOR 
have been shown to promote cellular survival and radioresis-
tance in various setups.48,49 Noteworthy, the inactivation of 
AKT was stable in the MCF-7 cell line. This is of certain inter-
est, because various studies report an upregulation of p-AKT 
after prolonged incubation with the dual inhibitor,27,31,39,50,51 
undermining the potential of NVP-BEZ235 in these setups. 
In addition to the stable AKT inhibition, activating PI3K 
mutations are the most common (up to 40%) genetic aber-
rations in primary BC.52 This provides a further rationale 
for targeting the PI3K/AKT/mTOR axis in BC. Therefore, 
concomitant treatment with NVP-BEZ235 and IR has the 
potential to greatly improve therapy outcome in a large set of 
BC patients.
Whereas we observed apoptosis in the MCF-7 cell line 
after prolonged NVP-BEZ235 treatment at all tested oxy-
gen conditions, no such apoptosis induction was observable 
in the MDA-MB-231 cell line. This is most likely because 
of the combination of the aforementioned inhibition of AKT, 
which was only observed in MCF-7 cells and which has been 
shown to induce cell death in several experiments53–55 and a 
non-mutated version of the p53 gene in the MCF-7 cell line. 
The fact that, unlike to most other solid human malignancies, 
mutations of the p53 gene occur with an inferior frequency in 
BC56 further supports the potential of NVP-BEZ235 in BC 
treatment.
Apart from the induction of cell death, which was 
dependent of the mutational status, we observed induction of 
autophagy in both cell lines after NVP-BEZ235 treatment in 
all tested oxygen conditions. In contrast to the current para-
digm of autophagy, in which accumulation of LC3-II protein 
occurs,57,58 we observed a strong reduction in LC3-I but no 
increase in LC3-II levels. However, Mizushima and Yoshi-
mori recently reported that the initially increased LC3-II level 
is degraded within a few hours after autophagy induction by 
delivery of LC-II to lysosomes.59 The induction of autophagy 
by NVP-BEZ235 is of interest, because its role in cancer is not 
completely understood yet, and this cellular process is highly 
discussed in the current literature.60,61 Several research groups 
aimed to exploit the autophagic process by inhibiting lyso-
somal degradation with bafilomycin A1 or chloroquine, which 
was shown to sensitize cells to IR.62–64 Whether simultane-
ous blockade of autophagy can enhance the NVP-BEZ235-
mediated radiosensitization of BC cell lines will be explored 
in future experiments to further enhance the radiosensitizing 
potential of NVP-BEZ235.
In addition to the aforementioned results, we observed 
reduced initial phosphorylation of H2AX along with reduced 
DNA repair after combined NVP-BEZ235 IR treatment. 
One possible explanation for these diminished initial DNA 
damages and their resolution in NVP-BEZ235-treated cells is 
the inhibition of DNA-PK, ATR, and ATM kinases as side 
targets of the dual inhibitor.43,65,66 Activation of these kinases 
is part of the DNA damage response and is involved in both 
formation and resolution of γH2AX.67,68 Therefore, their inhi-
bition can explain both the impaired induction and the pro-
tracted repair of DNA DSB. The fact that 24 hours after IR 
no differences between irradiated drug and DMSO-treated 
hypoxic cells were observed most likely is caused by reduced 
DNA repair mechanisms in hypoxic cells as reported else-
where.69,70 However, as reported by various research groups, 
inhibition of DNA repair mechanisms sensitized tumor cells 
to cytotoxic agents as IR.71–73 We therefore conclude, that 
DNA repair protraction, which was observed in all tested oxy-
gen conditions, might be another hallmark of radiosensitiza-
tion of the BC cell lines.
To sum up, treatment with the dual PI3K/mTOR inhib-
itor radiosensitized the TN MDA-MB-231 and the ER-
positive MCF-7 cell line in different physiological relevant 
oxygenation states, namely normoxic, reoxygenated after IR, 
and hypoxic. This oxygen-independent radiosensitization is 
most likely caused by inhibition of HIF-1α and PI3K/AKT/
mTOR signaling, DNA repair impairment, autophagy, and 
some extent induction of apoptosis. Furthermore, combined 
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drug-IR treatment decreased proliferation in both cell lines 
to a greater extent, than each treatment alone, indicating 
additive or synergistic effects. NVP-BEZ235 is in clinical trial 
phase I/II studies at the moment and especially the promising 
results in MCF-7 cells, along with the fact that the majority 
of human BCs are ER positive74 and harbor PI3K activating 
mutations  but are p53 wild-type,52,56 indicate a clinically rel-
evant application of NVP-BEZ235 in BC radiotherapy.
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esM figure 1. Representative colony forming abilities 
of MDA-MB-231 cancer cells treated with 100 nM NVP-
BEZ235 (filled symbols) or equal amounts of DMSO (empty 
symbols) prior to IR (A).
esM figure 2. Means (± standard deviation) of plating 
efficiencies (A and B), surviving fraction at 2 Gy (C and D) 
and dose yielding 10% survival (E and F) of MDA-MB-231 
(A, C and E) and MCF-7 (B, D and F).
esM figure 3. Representative Western blot analysis of 
expression levels of several marker proteins of the PI3K path-
way in MCF-7 (A and B) and MDA-MB-231 (C-E) cellular 
lysates, prepared thirty minutes (C), 24 h (A and D) and 48 h 
(B and E) after IR.
esM figure 4. Mean percentage of cells with hypodip-
loid DNA content and cellular debris in NVP-BEZ235 treated 
(grey columns) and irradiated (striped columns) normoxic, 
reoxygenated and hypoxic MDA-MB-231 cells 48 h after 
IR (A).
esM figure 5. Cell cycle phase distribution in MDA-
MB-231 (A) and MCF-7 (B) tumor cells treated with NVP-
BEZ235 and IR under different oxygen conditions.
esM figure 6. DNA DSBs as detected by phosphoryla-
tion of the histone H2AX in MDAMB-231 (A) And MCF-7 
(B) tumor cells treated with NVP-BEZ235 (grey columns) 
and IR (striped columns) under different oxygen conditions.
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